EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study

James L Rogers iD, Jessica Gacki-Smith iD, Rochell Yacat iD, Catherine Wicklund iD, Debra Duquette iD, John Friedewald iD, Matthew Cooper iD, Alexander Gilbert, Akansha Agrawal iD, Elisa J Gordon iD

Clinical Transplantation · 2024-12 · 38 (12)

DOI: 10.1111/ctr.70026 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2024-12-03. Written by James L Rogers and 9 co-authors. Institution: Vanderbilt School of Medicine, Nashville, Tennessee, USA. Major MEDLINE topics: Apolipoprotein L1, Living Donors, Focus Groups, Kidney Transplantation. Cited 5 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS, NIH, Northwestern Memorial Hospital Dixon Translational Research Innovation Award.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Living kidney donor (LKD) candidates of African ancestry are increasingly asked to undergo Apolipoprotein L1 ( APOL1 ) genetic testing during the donor evaluation process to better understand their risk of kidney disease. LKD candidates’ attitudes about using a clinical chatbot on APOL1 remain unknown. This study builds on prior work to culturally adapt the Gia ® (Genetic Information Assistant) chatbot on APOL1 by assessing donor, recipient, and community member attitudes about the Gia chatbot for enhancing the integration of APOL1 testing into the LKD clinical evaluation workflow.

Methods

This study involved focus groups and a post‐focus group survey in two US cities about the APOL1 Gia chatbot. Qualitative data were analyzed via thematic analysis, and descriptive statistics were used for demographic data.

Results

We conducted 10 focus groups including 54 participants (25 LKDs, 23 community members, and 6 living donor kidney transplant recipients of African ancestry). Five themes emerged: (1) participants supported LKD candidates using the Gia chatbot before the nephrologist clinic visit, (2) participants were interested in undergoing APOL1 testing after using Gia, (3) APOL1 testing costs may influence LKD candidates’ willingness to get tested, (4) patients of African ancestry may hold varying preferences for using chatbots in the healthcare setting, and (5) individual‐level barriers may limit the use of Gia in the healthcare setting.

Conclusions

Individuals of African ancestry were highly receptive to integrating the APOL1 chatbot into LKD candidate clinical evaluation, which bodes well for integrating chatbots into the APOL1 clinical genetic testing process.

Subjects

MeSH terms (MEDLINE)

Apolipoprotein L1Living DonorsFocus GroupsKidney TransplantationGenetic TestingHumansFemaleMaleMiddle AgedAdultDonor SelectionFollow-Up StudiesPrognosisAged

Author keywords

African AmericanAfrican ancestry genetic counselingBlackcommunity engagementevaluationfocus groupsinformed consentkidney diseasepatient‐centeredtransplantation

Substances

Apolipoprotein L1APOL1 protein, human

Authors and institutions

  • Vanderbilt School of Medicine, Nashville, Tennessee, USA.
  • Center for Health Services and Outcomes Research, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Medstar Georgetown Transplant Institute, Georgetown University Hospital, Washington, District of Columbia, USA.
  • Myriad Genetics, Salt Lake City, Utah.
  • Department of Medicine, Cardiology Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Medicine, Division of Nephrology and Hypertension I Department of Surgery, Division of Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

ORCID profiles: James L Rogers, Jessica Gacki-Smith, Rochell Yacat, Catherine Wicklund, Debra Duquette, John Friedewald, Matthew Cooper, Akansha Agrawal, Elisa J Gordon

Funding

  • NIDDK NIH HHS
  • NIH
  • Northwestern Memorial Hospital Dixon Translational Research Innovation Award
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Rogers, J. L., Gacki-Smith, J., Yacat, R., Wicklund, C., Duquette, D., Friedewald, J., Cooper, M., Gilbert, A., Agrawal, A., & Gordon, E. J. (2024). Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study. Clinical Transplantation, 38(12). https://doi.org/10.1111/ctr.70026

Vancouver

Rogers JL, Gacki-Smith J, Yacat R, Wicklund C, Duquette D, Friedewald J, et al. Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study. Clinical Transplantation. 2024;38(12). doi:10.1111/ctr.70026

BibTeX
@article{Rogers2024,
  author = {Rogers, James L and Gacki-Smith, Jessica and Yacat, Rochell and Wicklund, Catherine and Duquette, Debra and Friedewald, John and Cooper, Matthew and Gilbert, Alexander and Agrawal, Akansha and Gordon, Elisa J},
  title = {Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study},
  journal = {Clinical Transplantation},
  year = {2024},
  volume = {38},
  number = {12},
  doi = {10.1111/ctr.70026}
}
Start for free →